The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms.
Arthralgia
/ diagnosis
Bone Density Conservation Agents
/ administration & dosage
Bone Marrow
/ diagnostic imaging
Bone Marrow Diseases
/ diagnostic imaging
Cartilage, Articular
/ diagnostic imaging
Double-Blind Method
Female
Femur
Glucocorticoids
/ administration & dosage
Humans
Knee Joint
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Methylprednisolone
/ administration & dosage
Middle Aged
Multicenter Studies as Topic
Osteoarthritis, Knee
/ diagnostic imaging
Randomized Controlled Trials as Topic
Tibia
Time Factors
Zoledronic Acid
/ administration & dosage
MRI
bone marrow oedema
cartilage loss
knee osteoarthritis
knee pain
Journal
Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501
Informations de publication
Date de publication:
18 06 2021
18 06 2021
Historique:
received:
28
05
2020
revised:
26
09
2020
pubmed:
1
12
2020
medline:
20
8
2021
entrez:
30
11
2020
Statut:
ppublish
Résumé
To describe the association between change in subchondral bone marrow lesions (BMLs) and change in tibiofemoral cartilage volume and knee symptoms in patients with symptomatic knee OA. In total, 251 participants (mean 61.7 years, 51% female) were included. Tibiofemoral cartilage volume was measured at baseline and 24 months, and BML size at baseline, 6 and 24 months. Knee pain and function scores were evaluated at baseline, 6 and 24 months. Change in total and compartment-specific BML size was categorized according to the Least Significance Criterion. Linear mixed-effects models were used to evaluate the associations of change in BMLs over 6 and 24 months with change in cartilage volume over 24 months and knee symptoms over 6 and 24 months. Total BML size enlarged in 26% of participants, regressed in 31% and remained stable in 43% over 24 months. Compared with stable BMLs in the same compartment, enlarging BMLs over 24 months were associated with greater cartilage loss (difference: -53.0mm3, 95% CI: -100.0, -6.0), and regressing BMLs were not significantly associated with reduced cartilage loss (difference: 32.4mm3, 95% CI: -8.6, 73.3) over 24 months. Neither enlargement nor regression of total BML size over 6 and 24 months was associated with change in knee pain and function over the same time intervals. In subjects with symptomatic knee osteoarthritis and BMLs, enlarging BMLs may lead to greater cartilage loss but regressing lesions are not associated with reduced cartilage loss while neither is associated with change in knee symptoms.
Identifiants
pubmed: 33253381
pii: 6012794
doi: 10.1093/rheumatology/keaa716
doi:
Substances chimiques
Bone Density Conservation Agents
0
Glucocorticoids
0
Zoledronic Acid
6XC1PAD3KF
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2791-2800Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.